ChemoMetec A/S

BATS-CHIXE:CHEMMC Stock Report

Market Cap: DKK 7.8b

ChemoMetec Valuation

Is CHEMMC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CHEMMC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CHEMMC (DKK391.7) is trading above our estimate of fair value (DKK278.93)

Significantly Below Fair Value: CHEMMC is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CHEMMC?

Key metric: As CHEMMC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CHEMMC. This is calculated by dividing CHEMMC's market cap by their current earnings.
What is CHEMMC's PE Ratio?
PE Ratio57.2x
EarningsDKK 136.28m
Market CapDKK 7.79b

Price to Earnings Ratio vs Peers

How does CHEMMC's PE Ratio compare to its peers?

The above table shows the PE ratio for CHEMMC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.9x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
9.9x-15.2%UK£178.6m
C4XD C4X Discovery Holdings
2.9x-88.3%UK£30.3m
GNS Genus
140.2x37.0%UK£1.1b
CHEMMC ChemoMetec
57.2x17.2%DKK 7.8b

Price-To-Earnings vs Peers: CHEMMC is expensive based on its Price-To-Earnings Ratio (57.2x) compared to the peer average (52x).

Price to Earnings Ratio vs Industry

How does CHEMMC's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CHEMMC is expensive based on its Price-To-Earnings Ratio (57.2x) compared to the European Life Sciences industry average (37.1x).

Price to Earnings Ratio vs Fair Ratio

What is CHEMMC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CHEMMC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio57.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CHEMMC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CHEMMC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
DKK 545.00
0%
0.9%DKK 550.00DKK 540.00n/a2
Nov ’25DKK 401.40
DKK 438.33
+9.2%
16.2%DKK 505.00DKK 340.00n/a3
Oct ’25n/a
DKK 436.67
0%
16.8%DKK 505.00DKK 335.00n/a3
Sep ’25n/a
DKK 462.50
0%
2.7%DKK 475.00DKK 450.00n/a2
Aug ’25n/a
DKK 437.50
0%
8.6%DKK 475.00DKK 400.00n/a2
Jul ’25n/a
DKK 437.50
0%
8.6%DKK 475.00DKK 400.00n/a2
Jun ’25n/a
DKK 437.50
0%
8.6%DKK 475.00DKK 400.00n/a2
May ’25n/a
DKK 462.50
0%
13.5%DKK 525.00DKK 400.00n/a2
Apr ’25DKK 423.00
DKK 451.67
+6.8%
19.2%DKK 525.00DKK 330.00n/a3
Mar ’25n/a
DKK 451.67
0%
19.2%DKK 525.00DKK 330.00n/a3
Feb ’25n/a
DKK 448.33
0%
20.4%DKK 525.00DKK 320.00n/a3

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.00

7D

-8.8%

1Y

-6.0%

hVIVO

UK£178.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.25

7D

-10.9%

1Y

39.6%

Dermapharm Holding

€1.9b

Manufactures and sells off-patent branded pharmaceutical products in Germany.

0A5J

€34.28

7D

7.4%

1Y

-14.7%